Pertuzumab(Roche / Genentech)은 HER2 표적 항체로, Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target an epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 69.3% (ClinicalTrials.gov NCT01120184). PK: t½ 18 h. 차별점: Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Prolife.
HER2
Colorectal Cancer
Discontinued
ADC) values from breast MRI, and pathological remission after N
DM1) and trastuzumab deruxtecan (T-DXd) usi
Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Prolife
target an epidermal growth factor receptor
antibody-dependent cell-mediated cytotoxicity
apoptosis, respectively
HER2)-positive
Resistance to anti-HER2 therapies remains a major clinical challenge in the treatment of HER2+ breast cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Pertuzumab(Roche / Genentech)은 HER2 표적 항체로, Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: target an epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 69.3% (ClinicalTrials.gov NCT01120184). PK: t½ 18 h. 차별점: Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Prolife.
HER2
Colorectal Cancer
Discontinued
ADC) values from breast MRI, and pathological remission after N
DM1) and trastuzumab deruxtecan (T-DXd) usi
Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Prolife
target an epidermal growth factor receptor
antibody-dependent cell-mediated cytotoxicity
apoptosis, respectively
HER2)-positive
Resistance to anti-HER2 therapies remains a major clinical challenge in the treatment of HER2+ breast cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.